Overview
At Seattle Cancer Care Alliance, patients diagnosed with acute myelogenous leukemia (AML) receive state-of-the-art care from a team of specialists who focus almost exclusively on treating this disease. SCCA was formed, in part, to bring promising new treatments to patients faster. For the AML patient, this means more treatment options than might be found elsewhere, including participation in one or more of the 50 ongoing leukemia clinical research studies conducted at SCCA and its parent organizations, Fred Hutchinson Cancer Research Center and UW Medicine.
If your condition requires a bone marrow transplant, you should know that the Fred Hutchinson Transplant program at SCCA was ranked first in outcomes in a four-year study by the National Marrow Donor Program (NMDP) that measured one-year survival rates of patients among 122 transplant centers in the United States. The Hutchinson Center pioneered the use of bone marrow transplants as a treatment for blood diseases over 40 years ago. Since then thousands of patients with leukemia have come from around the world to receive bone marrow transplants at SCCA. Bone marrow transplants have transformed leukemia and related cancers, once thought incurable, into highly treatable diseases.
An NCI-Designated Cancer Center
National Cancer Institute (NCI)-designated Cancer Centers are recognized for their scientific excellence. They are a major source of discovery and development of more effective approaches to cancer prevention, diagnosis, and treatment. Seattle Cancer Care Alliance is an NCI-designated cancer center